We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Alere Inc. Inverness Medical Innovations Series B Convertible Perpetual Preferred Stock (delisted) | NYSE:ALR-B | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 402.00 | 0 | 01:00:00 |
From Jun 2019 to Jun 2024
WALTHAM, Mass., March 20, 2017 /PRNewswire/ --Â Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE: ALR-B). The dividend is payable on April 17, 2017 to holders of record of Series B stock at the close of business on April 3, 2017.
Such payment will cover the amount of all dividends accrued from January 1, 2017 through March 31, 2017.
About Alere
Alere believes that when diagnosing and monitoring health conditions, Knowing now matters™. Alere delivers on this vision by providing reliable and actionable information through rapid diagnostic tests, enhancing clinical and economic health outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for infectious disease, cardiometabolic disease and toxicology. For more information on Alere, please visit www.alere.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/alere-inc-declares-cash-dividend-on-its-series-b-convertible-perpetual-preferred-stock-300426372.html
SOURCE Alere Inc.
Copyright 2017 PR Newswire
1 Year Alere Inc. Inverness Medical Innovations Series B Convertible Perpetual Preferred Stock (delisted) Chart |
1 Month Alere Inc. Inverness Medical Innovations Series B Convertible Perpetual Preferred Stock (delisted) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
